Karima Bettayeb, PhD
EU Medical and Medical Affairs Director
Karima Bettayeb, PhD, joined the Acumen team in May 2024 as EU Medical/Medical Affairs Director. She has over 16 years’ experience in the field of neuroscience in multiple therapeutic areas such as Alzheimer’s disease, SMA, ALS, PSP, migraine, pain and oncology, as well as exposure to the various stages of the product life cycle.
Prior to joining Acumen Karima held the position of Senior Medical Advisor at Biogen in France where she was responsible for preparing the launch of several new drugs in the field of neuroscience,
including the launch of Aducanumab. Prior to that Karima worked as MSL at Eli Lilly USA where she covered the entire neurosciences pipeline, including Solanezumab. Additionally, she acquired field and office-based experience at Biogen and at Eli Lilly in the USA as an MSL, medical Liaison Manager, medical advisor and senior medical advisor.
Before entering the pharmaceutical industry, Karima acquired extensive scientific expertise in the field of Alzheimer’s disease. For eight years, she was a molecular and cell neuroscientist in the laboratory of Nobel laureate, Pr. Paul Greengard, at New York’s Rockefeller University where she focused on therapeutic targets affecting the progression of Alzheimer’s disease. Karima holds a PhD from the University of Rennes in biochemistry and cell biology where her work on kinase inhibitors led to the development of promising compounds for the treatment of cancer. Her work was published in thirteen publications and three patents, contributing to the creation of the biotech company, Manros Therapeutics.